Financial Performance - The company's revenue for Q1 2024 was CNY 330,434,802.62, representing a 96.41% increase compared to the same period last year[5]. - Total operating revenue for Q1 2024 was CNY 330,434,802.62, a significant increase from CNY 168,238,991.99 in Q1 2023, representing a growth of approximately 96.5%[18]. - Total operating costs for Q1 2024 reached CNY 682,453,542.19, compared to CNY 506,546,573.98 in Q1 2023, indicating an increase of about 34.7%[18]. - Net loss for Q1 2024 was CNY 348,921,696.49, compared to a net loss of CNY 323,774,631.80 in Q1 2023, showing an increase in loss of about 7.8%[19]. - The total comprehensive loss for Q1 2024 was CNY -372,204,285.59, compared to CNY -326,630,103.58 in Q1 2023, reflecting an increase in comprehensive loss of about 13.9%[19]. Cash Flow - The net cash flow from operating activities was a negative CNY 426,289,929.83[5]. - Cash flow from operating activities resulted in a net outflow of CNY -426,289,929.83 in Q1 2024, worsening from CNY -349,845,397.38 in Q1 2023[20]. - Cash flow from investing activities showed a net outflow of CNY -81,362,490.71 in Q1 2024, compared to CNY -584,089,411.54 in Q1 2023, indicating a reduction in outflow[21]. - Cash flow from financing activities generated a net inflow of CNY 401,987,661.35 in Q1 2024, contrasting with an outflow of CNY -47,838,016.27 in Q1 2023[21]. - The ending cash and cash equivalents balance as of Q1 2024 was CNY 619,732,575.42, down from CNY 1,086,332,437.19 at the end of Q1 2023[21]. Shareholder Information - The company reported a total of 5,422 common shareholders at the end of the reporting period[10]. - The top shareholder, HKSCC NOMINEES LIMITED, held 189,566,728 shares, accounting for 34.83% of total shares[10]. - The company had a total of 5,422 shareholders as of the reporting date, with 5,397 being A-share holders and 25 being H-share holders[12]. - The top 10 shareholders held a total of 189,566,728 shares, representing a significant portion of the company's equity[12]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,478,656,892.82, a decrease of 0.90% from the previous year[6]. - The total liabilities as of March 31, 2024, were RMB 2,400,104,697.08, compared to RMB 2,090,972,550.70 at the end of 2023, indicating an increase in liabilities[16]. - The total equity attributable to shareholders decreased to RMB 3,078,552,195.74 from RMB 3,437,268,153.89[17]. - The company reported a net loss of RMB 3,202,432,084.51 in retained earnings as of March 31, 2024, compared to a loss of RMB 2,853,510,388.02 at the end of 2023[17]. - The inventory increased to RMB 751,473,242.66 from RMB 741,559,576.19, reflecting a rise in stock levels[16]. - The company’s short-term borrowings rose significantly to RMB 574,000,648.97 from RMB 284,276,638.87, indicating increased leverage[16]. Research and Development - Research and development expenses totaled CNY 331,178,800.01, an increase of 32.62% year-on-year[6]. - The ratio of R&D expenses to revenue was 100.23%, a decrease of 48.20 percentage points due to the significant increase in revenue[6][9]. - Research and development expenses amounted to CNY 331,178,800.01 in Q1 2024, up from CNY 249,722,218.25 in Q1 2023, reflecting a rise of approximately 32.5%[18]. Earnings Per Share - Basic and diluted earnings per share were both -CNY 0.65[6]. - The company reported a basic and diluted earnings per share of CNY -0.65 for Q1 2024, compared to CNY -0.60 in Q1 2023[19].
荣昌生物(09995) - 2024 Q1 - 季度业绩